Literature DB >> 6890426

Renal function and digoxin clearance during quinidine therapy.

K Schenck-Gustafsson, A Juhlin-Dannfelt, R Dahlqvist.   

Abstract

To investigate further the handling of digoxin by the kidneys during quinidine therapy, clearances of digoxin, 51Cr-EDTA, PAH and endogenous creatinine were measured together with beta 2-microglobulin in the urine before and during quinidine therapy in 10 patients on maintenance digoxin therapy. Renal clearance of digoxin (corrected for 30% plasma binding) decreased on the average by 55% (137 +/- 73 to 73 +/- 25 ml/min, mean +/- SD). The steady state plasma concentration of digoxin increased more than twofold (1 . 0 +/- 0 . 34 to 2 . 5 +/- 0 . 79 nmol/L, mean +/- SD). The clearances of 51Cr-EDTA and PAH were not altered during quinidine therapy, indicating that neither glomerular filtration nor total renal blood flow changed when quinidine was added. The ratio of the renal clearance of unbound digoxin to that of the glomerular filtration rate was above one for all 10 patients before quinidine, indicating the involvement of tubular secretion in the renal elimination of digoxin. After the administration of quinidine this ratio decreased in all patients (from 1 . 51 +/- 0 . 30 to 0 . 83 +/- 0 . 38, mean +/- SD). Some patients had ratios well below one suggesting re-absorption of digoxin. Beta 2-microglobulin excretion was unchanged during treatment with quinidine. It is concluded that a significant portion of the renal elimination of digoxin in man results from tubular secretion and that this excretory mechanism is inhibited by quinidine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6890426     DOI: 10.1111/j.1475-097x.1982.tb00046.x

Source DB:  PubMed          Journal:  Clin Physiol        ISSN: 0144-5979


  5 in total

Review 1.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

2.  Interaction study of fenoldopam--digoxin in congestive heart failure.

Authors:  E Strocchi; F Tartagni; P L Malini; G Valtancoli; E Ambrosioni; F Pasinelli; E Riva; L M Fuccella
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 3.  Pharmacokinetic drug interactions between digoxin and antiarrhythmic agents and calcium channel blocking agents: an appraisal of study methodology.

Authors:  E M Antman; J M Arnold; P L Friedman; T W Smith
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

Review 4.  Clinical pharmacokinetic significance of the renal tubular secretion of digoxin.

Authors:  G Koren
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

5.  Quinidine-induced changes in serum and skeletal muscle digoxin concentration; evidence of saturable binding of digoxin to skeletal muscle.

Authors:  T Jogestrand; K Schenck-Gustafsson; R Nordlander; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.